证券代码：605266 证券简称：健之佳 公告编号：2024-102 健之佳医药连锁集团股份有限公司 关于回购注销部分限制性股票减少注册资本暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 健之佳医药连锁集团股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日召开第六届董事会第八次会议、2024 年 11 月 14 日召开 2024 年第二次临时股 东会，审议通过了《关于终止实施 2024 年限制性股票激励计划暨回购注销限制 性股票的议案》。 本次注册资本减少为公司终止实施 2024 年限制性股票激励计划，不会对公 司的经营业绩产生重大影响，也不会影响公司管理团队的勤勉尽职。 1 / 2 鉴于公司本次回购注销限制性股票将导致注册资本减少，根据《中华人民共 和国公司法》（以下简称"《公司法》"）等相关法律、法规的规定，公司特此通知 债权人，债权人自接到通知之日起三十日内，未接到通知的自本公告之日起四十 五日内，有权要求公司清偿债务或者提供相应的担保。 公司债权人如逾期未行使 ...

健之佳医药连锁集团股份有限公司 1 健之佳医药连锁集团股份有限公司 | 会议须知 | | --- | | 会议议程 | | 关于终止实施2024年限制性股票激励计划暨回购注销限制性股票的议案 7 | | 关于修订《公司章程》的议案 | 2 健之佳医药连锁集团股份有限公司 为维护全体股东的合法权益，确保健之佳医药连锁集团股份有限公司（以下 简称"公司"）股东会的正常秩序和议事效率，保证股东会的顺利进行，根据《中 华人民共和国公司法》、《中华人民共和国证券法》、《健之佳医药连锁集团股 份有限公司章程》及《股东会议事规则》的规定，特制定本次股东会须知如下： 一、股东参加股东会，应当认真履行其法定义务，不得侵犯其他股东权益。 二、出席会议的股东（或股东代理人）须在会议召开前15分钟到达会议现场 办理签到手续，并请按规定出示本人身份证或其他能够表明其身份的有效证件或 证明、股东账户卡、加盖法人公章的企业法人营业执照复印件（法人股东）、授 权委托书（股东代理人）、持股凭证等文件，经验证后领取会议资料，方可出席会 议。 在会议主持人宣布现场出席会议的股东和股东代理人人数及所持有表决权 的股份总数后，会议终止登记。未签到登记 ...

2、本公司在上市公司本次股票交易异常波动期间,不存在买卖上市公司股 票的情况。 特此函复。 深圳 公司 4月 健之佳医药连锁集团股份有限公司: 贵公司《关于健之佳医药连锁集团股份有限公司股票交易异常波动问询函》 已悉收,本公司作为健之佳医药连锁集团股份有限公司(以下简称"上市公司") 控股股东,经认真自查,现回复如下: 1、除公司已披露事项外,本公司不存在其他与上市公司有关的应披露而未 披露的重大信息,包括但不限于重大资产重组、股份发行、收购、债务重组、业 务重组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 《关于健之佳医药连锁集团股份有限公司股票交易异常波动问询 函》的回函 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：605266 证券简称：健之佳 公告编号：2024-100 健之佳医药连锁集团股份有限公司 股票交易异常波动公告 健之佳医药连锁集团股份有限公司（以下简称"公司"）股票于 2024 年 10 月 31 日、11 月 1 日、11 月 4 日连续 3 个交易日内日收盘价格涨幅偏离值累 计超过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常 波动情形。 经公司自查，并向控股股东深圳市畅思行实业发展有限责任公司（以下简称 "畅思行"）及实际控制人蓝波、舒畅夫妇书面确认，截止本公告日，不存在影 响公司股票交易异常波动的重大事项，不存在其他与公司有关的应披露而未披露 的重大信息，包括但不限于重大资产重组、股份发行、收购、债务重组、业务重 组、资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引 进战略投资者等重大事项。 经公司自查，并向控股股东畅思行和实际控制人蓝波、舒畅发函确认，核查 结果如下： （一）生产经营情况 公司目前经营 ...

1、除已披露事项外,本人不存在其他与上市公司有关的应披露而未披露的 重大信息,包括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、 资产剥离、资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战 略投资者等重大事项。 2、本人在上市公司本次股票交易异常波动期间,不存在买卖上市公司股票 的情况。 特此函复。 蓝波: P 舒畅: 2024年 11月 4日 《关于健之佳医药连锁集团股份有限公司股票交易异常波动的问询 函》之回函 健之佳医药连锁集团股份有限公司: 贵公司《关于健之佳医药连锁集团股份有限公司股票交易异常波动问询函》 已悉收,本人作为健之佳医药连锁集团股份有限公司(以下简称"上市公司") 实际控制人,经认真自查,现回复如下: ...

Investment Rating - The report maintains a "Buy" rating for the company [2][5]. Core Views - The company's revenue growth has slowed due to a challenging consumption and policy environment, leading to significant pressure on profits. However, a recovery is expected in 2025 as the company adjusts its product categories and controls costs [2][3]. Financial Summary - For the first three quarters of 2024, the company achieved revenue of 6.735 billion yuan, a year-on-year increase of 3.6%, while net profit attributable to shareholders was 101 million yuan, down 63.8%. In Q3 2024, revenue was 2.25 billion yuan, up 4.08%, with net profit of 38 million yuan, down 68.46% [3][4]. - The company has adjusted its earnings per share (EPS) forecasts for 2024-2026 to 1.14, 1.70, and 1.98 yuan, respectively, down from previous estimates of 2.92, 3.54, and 4.22 yuan [3]. - The target price has been revised down to 28.90 yuan, reflecting a price-to-earnings (PE) ratio of 17 times for 2025 [3][5]. Revenue and Profitability - Revenue growth has been impacted by several factors, including a decline in medical insurance settlement income, high proportions of new stores with lower output, and a challenging consumption environment affecting traditional Chinese medicine and health food products [3]. - The company has seen an increase in non-drug revenue, primarily due to the introduction of high-margin skincare products [3]. Store Operations - As of Q3 2024, the total number of stores reached 5,501, with 75 new openings and 18 closures. The company is focusing on improving store operational quality amid a competitive market [3]. Cost Management - The company is experiencing increased expense ratios due to fixed costs associated with store operations. In Q3 2024, the sales, management, and financial expense ratios increased year-on-year [3]. - The company plans to enhance its own brand product development and control costs to mitigate the decline in gross margins [3]. Future Outlook - The company is expected to benefit from improvements in the consumption and policy environment, as well as the further clearing out of small pharmacies, leading to a potential recovery in performance in 2025 [3].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 30.3 yuan, compared to the current price of 23.31 yuan [1]. Core Views - The company's revenue for the first three quarters of 2024 reached 6.74 billion yuan, with a year-on-year increase of 3.6%. However, the net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses saw significant declines of 63.8% and 64.3% respectively, primarily due to the ongoing implementation of medical reform policies [1][2]. - The company has been adjusting its operational strategies to mitigate the impact of policy changes, focusing on enhancing non-medical insurance revenue through differentiated competition and professional services [2]. - Store expansion has slowed down, with a net increase of 385 stores in the first nine months of 2024, bringing the total to 5,501 stores, a 7.5% increase from the beginning of the year [2]. - The gross profit margin has come under pressure, with a decline of 1.2 percentage points to 36.8% in Q3 2024, while the net profit margin decreased by 3.9 percentage points to 1.7% [2]. Financial Summary - The company forecasts net profits attributable to the parent company for 2024-2026 to be 210 million, 237 million, and 268 million yuan, reflecting a year-on-year change of -49%, +13%, and +13% respectively [2][3]. - The projected revenue for 2024 is 9.35 billion yuan, with a growth rate of 3.0%, and is expected to reach 10.28 billion yuan in 2025, growing by 10.0% [3]. - The company's total assets are projected to increase from 9.949 billion yuan in 2023 to 11.304 billion yuan in 2024 [6].

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Insights - The company has shown steady growth in its traditional Chinese and Western medicine business, with a revenue increase of 4.3% in the first nine months of 2024, accounting for 76.8% of total sales [1][2]. - The company reported a total revenue of 6.74 billion yuan for the first three quarters of 2024, reflecting a 3.6% year-on-year increase, while the net profit attributable to shareholders decreased by 63.8% to 100 million yuan [2][4]. - The company is expanding its store network through a combination of self-built and acquired stores, with a total of 5,501 stores as of Q3 2024, representing a 7.5% increase from the beginning of the year [2][3]. Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 2.25 billion yuan, up 4.1% year-on-year, but the net profit attributable to shareholders fell by 68.5% to 40 million yuan [2]. - The projected net profits for 2024-2026 are estimated at 250 million yuan, 310 million yuan, and 360 million yuan respectively [1][4]. Business Expansion - The company is focusing on increasing the number and scale of stores in county-level and above markets, with 94.8% of its retail stores located in these areas [3]. - The company has a strategic plan to penetrate deeper into the market, particularly in cities with significant growth potential, while maintaining a strong presence in provincial capitals [3]. Revenue and Profitability Forecast - The company anticipates a revenue growth rate of 3% for retail business in 2024, with a projected compound annual growth rate of 30% for its professional services to pharmaceutical and convenience suppliers [6]. - The overall revenue forecast for 2024-2026 is expected to grow from 8.39 billion yuan in 2024 to 10.71 billion yuan in 2026, with a corresponding increase in gross margin [6][8].

证券代码：605266 证券简称：健之佳 公告编号：2024-099 健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司（以下简称"公司"） 于 2024 年 9 月 19 日召开第六届董事会第七次会议审议通过了《关于回购公司股份的方案》，同意公 司使用自有资金通过集中竞价交易方式回购公司部分股份，所回购股份将在披露 回购结果暨股份变动公告 12 个月后根据相关规则择机采用集中竞价交易方式出售。 本次回购金额不低于人民币 2,000 万元且不超过人民币 3,000 万元（均含本数）， 回购股份价格不超过人民币 29.80 元/股（含）。本次回购实施期限为自公司董事 会审议通过本次回购方案之日起不超过 3 个月。具体内容详见公司在上海证券交 易所网站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份方案暨 回购报告书》（公告编号：2024-080）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购股份期间，上市公司应当每个月的前三个 交易日内，公告截至上月末的回购进展情况。现公司将截至 202 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-098 健之佳医药连锁集团股份有限公司 关于回购股份事项前十大股东及前十大无限售条件股东 持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、前十名股东持股情况 1 | 7 | 国泰基金管理有限公司－社保基金四二一 | 2,454,276 | 1.57 | | --- | --- | --- | --- | | | 组合 | | | | 8 | 中国建设银行股份有限公司－国泰大健康 | 2,218,272 | 1.42 | | | 股票型证券投资基金 | | | | 9 | 健之佳医药连锁集团股份有限公司－2024 | 2,051,152 | 1.31 | | | 年员工持股计划 | | | | 10 | 兴业银行股份有限公司－融通鑫新成长混 | 1,998,989 | 1.28 | | | 合型证券投资基金 | | | 注：以上股东的持股数量为合并普通账户和融资融券信用账户后的持股数量 总数。 | 序号 | 股东名称 | 持有数量 | 占公司无限 ...